The proposed research is aimed at continuing investigations at evaluating the compound AMR-MeOAC as multi-factorial anti breast cancer agent that kills the pancreatic cancer cells effectively.The specific aims of the project are the following: Aim 1: To determine the antiproliferative effect of AMR-MeOAc as oncogenic PIK3CA targeted cancer preventive agent on immortalised normal mammary epithelial MCF-10A cells and antiproliferative effect in breast cancer MCF-7 cells result from decreased VEGF expression by transcriptional downregulation of PI3K/Akt. Aim 2: To assess the efficacy of AMR-MeOAc inhibition of VEGF and PI3K/Akt signaling against hormone-sensitive breast cancer xenograft. We expect that the systematic investigation of AMR-Me and AMR-MeOAc in functional in vitro bioassays and in vivo tumor studies in mice will unveil a new anticancer agent for development into a clinically effective compound for the prevention and treatment of breast cancer.